Previous 10 | Next 10 |
Christophe Bourdon’s Deep Commercialization Background and Vast International Experience Make Him the Ideal CEO For Orphazyme CEO Relocation to Copenhagen Seen as a Positive Sign of the Commercial Potential of Arimoclomol CytRx Corporation (OTCQB: CYTR...
CytRx Corporation (OTCQB: CYTR) (“CytRx” or the “Company”), a specialized biopharmaceutical company focused on research and development for the oncology and neurodegenerative disease categories, today announced that Steven A. Kriegsman, Chairman and Chief Exe...
CytRx Corporation (OTCQB: CYTR) (“CytRx” or the “Company”), a specialized biopharmaceutical company focused on research and development for the oncology and neurodegenerative disease categories, today announced that it is now a part of the LD Micro Index ...
Biopharmaceutical company CytRx (CYTR) says that NantKwest and ImmunityBio's ongoing Phase 2 clinical trials of a novel combination immunotherapy – which include CytRx’s licensed drug aldoxorubicin – for locally advanced or metastatic pancreatic cancer have...
NantKwest and ImmunityBio’s QUILT 88 Trial Shows Novel Combination Immunotherapy, Which Includes Aldoxorubicin, Has More Than Doubled Historic Median Survival Rates in Patients CytRx Corporation (OTCQB:CYTR) (“CytRx” or the “Company”), ...
CytRx Corporation ([[CYTR]] -5.4%) announces that the FDA has extended the review period for its New Drug Application for arimoclomol to treat Niemann-Pick Disease Type C (“NPC”) by three months. The updated PDUFA target action date is June 17, 2021.Despite the delay, ...
CytRx Corporation (OTCQB: CYTR) (“CytRx” or the “Company”), a specialized biopharmaceutical company focused on research and development for the oncology and neurodegenerative disease categories, today provided an update on the U.S. Food and Drug Administratio...
Highlights That Potential Merger Can Help Accelerate Current and Future Clinical Programs Utilizing CytRx’s Licensed Drug Aldoxorubicin CytRx Corporation (OTCQB: CYTR) (“CytRx” or the “Company”), a specialized biopharmaceutical company ...
CytRx (CYTR) has announced that Orphazyme A/S (ORPH) announces the expansion of its U.S. presence and workforce ahead of potential Food and Drug Administration approval of arimoclomol for the treatment of Niemann-Pick disease Type C. CytRx has an agreement with Orphazyme that can yield potent...
Highlights Orphazyme’s Establishment of U.S. Headquarters in Chicago and Recruitment of More Than 30 U.S. Employees Comments That Orphazyme’s Investments in the U.S. are Intended to Support Regulatory Efforts and the Prospective Commercialization of Arimocl...
News, Short Squeeze, Breakout and More Instantly...
LadRx Corporation (OTCQB: LADX) (“LadRx” or the “Company”), a biopharmaceutical innovator focused on research and development of life-saving cancer therapeutics, today announced it is changing its OTCQB ticker symbol from CYTR to LADX effective Thursday, Octo...
The New LadRx Corporation Name Will Be Effective on September 26, 2022 and Will Continue to Trade Under the Ticker CYTR until the new symbol has been approved by FINRA CytRx Corporation (OTCQB: CYTR) (“CytRx” or the “Company”), a biopharmaceut...
Patent Protects the LADR Platform and Drugs Employing LADR CytRx Corporation (OTCQB: CYTR) (“CytRx” or the “Company”), a biopharmaceutical innovator focused on research and development of life-saving cancer therapeutics, today announced it has...